FogPharma
Creating extraordinary medicines.
Cambridge, United States · Founded 2016 · $801.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- fogpharma.com
- Total Funding
- $801.0M
- Last Round
- $305.0M Series FJan 2025
- Rounds
- 5
About
FogPharma (rebranded as Parabilis Medicines in October 2024) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company pioneered a new class of alpha-helical peptides called Helicons™, capable of modulating intracellular proteins historically beyond the reach of conventional medicines. Its lead program, FOG-001 (zolucatetide), is the first and only direct inhibitor of the beta-catenin transcriptional co-activator complex and is in active clinical development across multiple tumor types including adamantinomatous craniopharyngioma. In January 2026, Parabilis raised an oversubscribed $305 million financing to advance FOG-001 and its broader Helicon platform.
Summary
FogPharma is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $801.0M in total across 5 rounds, most recently a $305.0M Series F round in Jan 2025. Investors include RA Capital Management, venBIO Partners and ARCH Venture Partners.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Jan 2025
Sign up to see all 5 rounds
Series B through Series F — per-round amounts, valuations, and who invested in each round.
Investors
RA Capital Management
2 rounds
venBIO Partners
2 rounds
ARCH Venture Partners
2 rounds
Nextech Invest
1 round
6 Dimensions Capital
1 round
Cormorant Asset Management
1 round
Rock Springs Capital
1 round
General Catalyst
1 round
Marshall Wace
1 round
Invus
1 round
Milky Way Investments Group
1 round
Fidelity Management
1 round
GV
1 round
Blue Pool Capital
1 round
Deerfield Management
1 round
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Biotechnology company using AI to learn from life's chemistry and discover medicines 4X faster.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/fogpharma"><img src="https://indexed.vc/api/badge/company/fogpharma" alt="FogPharma on Indexed.vc" width="260" height="76" /></a>